BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24300044)

  • 1. Reply to Simon, Shah et al, and Hartzema and Chen.
    Bartsch SM; Umscheid CA; Fishman N; Lee BY
    Clin Infect Dis; 2014 Feb; 58(4):605-7. PubMed ID: 24300044
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of fidaxomicin for Clostridium difficile treatment.
    Simon MS
    Clin Infect Dis; 2014 Feb; 58(4):603. PubMed ID: 24300043
    [No Abstract]   [Full Text] [Related]  

  • 3. Is fidaxomicin worth the cost? The verdict is still out!
    Hartzema AG; Chen C
    Clin Infect Dis; 2014 Feb; 58(4):604-5. PubMed ID: 24300046
    [No Abstract]   [Full Text] [Related]  

  • 4. A pharmacy concierge service to optimize fidaxomicin therapy.
    Bookstaver PB; Capino AC; Bookstaver NK
    Am J Health Syst Pharm; 2014 Jun; 71(12):986-7. PubMed ID: 24865752
    [No Abstract]   [Full Text] [Related]  

  • 5. An economic analysis: is fidaxomicin worth the cost?
    Shah H; Doyle JJ; Belletti DA
    Clin Infect Dis; 2014 Feb; 58(4):603-4. PubMed ID: 24300041
    [No Abstract]   [Full Text] [Related]  

  • 6. Fewer recurrent infections of C. difficile seen with fidaxomicin. This new class of antibiotic--the macrocycles--has a greater sustained response against re-infection than vancomycin.
    Morrow T
    Manag Care; 2011 Jul; 20(7):49-50. PubMed ID: 21848202
    [No Abstract]   [Full Text] [Related]  

  • 7. Fidaxomicin failures in recurrent Clostridium difficile infection: a problem of timing.
    Orenstein R
    Clin Infect Dis; 2012 Aug; 55(4):613-4. PubMed ID: 22610922
    [No Abstract]   [Full Text] [Related]  

  • 8. The search for effective treatment of Clostridium difficile infection.
    DuPont HL
    N Engl J Med; 2011 Feb; 364(5):473-5. PubMed ID: 21288079
    [No Abstract]   [Full Text] [Related]  

  • 9. Fidaxomicin for Clostridium difficile Infection.
    Safdar N; Craig WA
    N Engl J Med; 2011 May; 364(19):1875; author reply 1875-6. PubMed ID: 21561360
    [No Abstract]   [Full Text] [Related]  

  • 10. Fidaxomicin for Clostridium difficile infection.
    Linsky A; Gupta K; Hermos JA
    N Engl J Med; 2011 May; 364(19):1875; author reply 1875-6. PubMed ID: 21561361
    [No Abstract]   [Full Text] [Related]  

  • 11. Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin.
    Biswas JS; Patel A; Otter JA; Wade P; Newsholme W; van Kleef E; Goldenberg SD
    J Hosp Infect; 2015 Jul; 90(3):267-70. PubMed ID: 25728208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fidaxomicin, a new treatment for Clostridium difficile infections.
    Epstein L; Golan Y
    Drugs Today (Barc); 2012 Feb; 48(2):101-8. PubMed ID: 22384450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review: NAATs diagnose C difficile; vancomycin improves cure, and fidaxomicin reduces recurrence.
    Zar FA
    Ann Intern Med; 2016 Jul; 165(2):JC4. PubMed ID: 27429316
    [No Abstract]   [Full Text] [Related]  

  • 14. Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection.
    Hardesty JS; Juang P
    Pharmacotherapy; 2011 Sep; 31(9):877-86. PubMed ID: 21923589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fidaxomicin therapy in critically ill patients with Clostridium difficile infection.
    Penziner S; Dubrovskaya Y; Press R; Safdar A
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1776-81. PubMed ID: 25534722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small Molecules Take A Big Step Against Clostridium difficile.
    Beilhartz GL; Tam J; Melnyk RA
    Trends Microbiol; 2015 Dec; 23(12):746-748. PubMed ID: 26547239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypersensitivity reactions associated with fidaxomicin use.
    Iarikov DE; Alexander J; Nambiar S
    Clin Infect Dis; 2014 Feb; 58(4):537-9. PubMed ID: 24178248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection.
    Venugopal AA; Johnson S
    Clin Infect Dis; 2012 Feb; 54(4):568-74. PubMed ID: 22156854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.
    Rubio-Terrés C; Cobo Reinoso J; Grau Cerrato S; Mensa Pueyo J; Salavert Lletí M; Toledo A; Anguita P; Rubio-Rodríguez D; Watt M; Gani R
    Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2213-23. PubMed ID: 26407619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clostridium difficile infecion--diagnostics, prevention and treatment].
    Piekarska M; Wandałowicz AD; Miigoć H
    Pol Merkur Lekarski; 2014 Apr; 36(214):278-82. PubMed ID: 24868904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.